Post-Doctoral Neurosurgery Research Fellow Johns Hopkins University Johns Hopkins University School of Medicine Baltimore, MD, US
Disclosure(s):
Abdel-Hameed Al-Mistarehi, MD: No financial relationships to disclose
Introduction: Spinal chordomas are rare, malignant tumors arising from notochordal remnants, with a relatively indolent clinical course but significant local morbidity. This study utilized the National Cancer Database (NCDB) to identify predictors of 30-day readmission following spinal or sacral chordoma resection.
Methods: Data was collected retrospectively from the NCDB for patients undergoing spinal or sacral chordoma tumor resection between 2004 and 2017. Collected data included demographics, medical history, tumor characteristics, and treatment protocols. Patients were dichotomized by 30-day readmission status. Statistical analyses focused on identifying significant predictors for readmission.
Results: A total of 1204 patients were included, of whom 106 (8.8%) experienced a 30-day readmission. Significant predictors of 30-day readmission included a Charlson Comorbidity Score of ≥2 (OR=3.03; 1.522–6.036; p=0.002) and longer duration from diagnosis to surgery (OR=1.01; 1.002–1.013; p=0.002). Black race showed a trend toward significance (OR=3.92; 0.974–15.76; p=0.055), while other factors, including age, tumor size, and extent of resection, were not significant.
Conclusion : Higher Charlson Comorbidity Scores and longer time from diagnosis to surgery were identified as predictors for 30-day readmission. Future studies should focus on optimizing preoperative conditions and reducing delays to surgery to minimize readmission risks.
.jpg)
